GB1603566A – Steroidal naphthalenes
– Google Patents
GB1603566A – Steroidal naphthalenes
– Google Patents
Steroidal naphthalenes
Download PDF
Info
Publication number
GB1603566A
GB1603566A
GB16545/78A
GB1654578A
GB1603566A
GB 1603566 A
GB1603566 A
GB 1603566A
GB 16545/78 A
GB16545/78 A
GB 16545/78A
GB 1654578 A
GB1654578 A
GB 1654578A
GB 1603566 A
GB1603566 A
GB 1603566A
Authority
GB
United Kingdom
Prior art keywords
steroid
accordance
alkyl
hydrogen
formula
Prior art date
1977-05-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB16545/78A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1977-05-12
Filing date
1978-04-26
Publication date
1981-11-25
1978-04-26
Application filed by ER Squibb and Sons LLC
filed
Critical
ER Squibb and Sons LLC
1981-11-25
Publication of GB1603566A
publication
Critical
patent/GB1603566A/en
Status
Expired
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
C07J53/002—Carbocyclic rings fused
Description
PATENT SPECIFICATION ( 11) 1 603 566
CD ( 21) Application No 16545/78 ( 22) Filed 26 April 1978 ( 31) Convention Application No796292 ( 19) 1 ( 32) Filed 12 May 1977 in Mf ( 33) United States of America (US) ( ( 44) Complete Specification published 25 Nov 1981 ( 51) INT CLU C 07 J 31/00 A 61 K 31/565 ( 52) Index at acceptance C 2 U 23 4 A 2 A 4 B 14 B 2 B 4 CIOA 4 CX 4 DX 4 N 6 B 4 N 6 Y 4 N 95 6 A 1 6 D 8 A 1 ( 72) Inventor RAVI K VARMA ( 54) STEROIDAL NAPHTHALENES ( 71) We, E R SQUIBB & SONS, INC, a corporation organized and existing under the laws of the State of Delaware, United States of America, of Lawrenceville-Princeton Road, Princeton, New Jersey, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in 5 and by the following statement:-
This invention provides novel steroids having the formula RR R R 6 and the 1,2-dehydro derivatives thereof, wherein X is -S-, O O ii II -S or -S 10 R, is alkyl, aryl or acyloxyalkyl; R 2 and R 3 are the same or different and are hydrogen, alkyl, alkoxy, carboalkoxy, formyl, O O 11 11 II II alkyl-C-, alkyl-C-O-, hydroxy, halogen, phenyl or cyano, with the proviso that when R 2 and R 3 are different, one of R 2 and R 3 is hydrogen; R 4 is carbonyl, /3hydroxymethylene or /3 15 acyloxymethylene; Rs is hydrogen or halogen; and R 6 is hydrogen or fluorine; wherein the term «aryl» refers to phenyl or phenyl substituted with one or two alkyl, alkoxy or halogen substituents; the term «acyloxy» refers to a group having the formula Y-C-O 20 wherein Y is alkyl or aryl; and the terms «alkyl» and «alkoxy» refer to groups having I to 10 carbon atoms These new steroids can be used as antiinflammatory agents and the invention provides pharmaceutical compositions comprising such steroids and a pharmaceutical carrier.
2 1603566 In formula I above, and throughout the specification, the symbols are as defined above A dotted line in the 1,2 position of a structural formula in this disclosure indicates the optional presence of ethylenic unsaturation The term «halogen», as used throughout the specification, refers to fluorine, chlorine, bromine and iodine 5 The steroids of this invention can be prepared utilizing as starting materials androstenes having the formula 0 < 6 Reaction of an androstene of formula II with a thiol compound having the formula R;-SH III 10 in the presence of a Lewis acid (e g, boron trifluoride etherate), yields an intermediate having the formula 1 S IV 0 odJ 6.
In formulas III and IV, and throughout the specification, R', is alkyl or aryl The reaction can be run in an organic solvent (e g, a halogenated hydrocarbon) , or a 15 mixture of organic solvents The use of some glacial acetic acid improves yields.
Reaction conditions are not critical, and the reaction can be conveniently run at room temperature, preferably in an inert atmosphere (e g, argon or nitrogen).
Better yields may be obtained with relatively short reaction times (less than 1 hour).
An androstene of formula IV can be converted to the corresponding steroid 20 having the formula 2 '1 V by simply heating the steroid in an inert solvent (e g, diethylbenzene or dichlorobenzene).
The steroid products of formula I wherein R 1 is alkyl or aryl and X is divalent 25 sulfur can be obtained by reacting a steroid of formula V with a benzocyclobutene having the formula R 2 VI The reaction can be run with, or without, an inert solvent Preferably the reaction will be run neat, in an inert atmosphere, at temperatures up to the boiling 30 point of the reaction mixture The product of the above reaction has the formula 1 603 566 3 1,603,566 3 R 1 A R -% X VII H 3 0 IH R'6 Oxidation of an androstene of formula VII with a peracid (e g, mchloroperbenzoic acid), a peracid salt (e g, sodium m-periodate) or a peroxide (e.g, hydrogen peroxide) yields the corresponding sulfinyl product having the formula 5 1 9 k S R 5.s' _R 2 . R @ VIII I R 6 or the corresponding sulfonyl product having the formula R 1 l R 2 O S-O O 2 z R.
IX I I l The use of one equivalent of oxidizing agent will yield predominantly the sulfinyl derivative of formula VIII and the use of two or more equivalents of oxidizing agent 10 will yield predominantly the sulfonyl derivative of formula IX.
Metachloroperbenzoic acid is the preferred oxidizing agent The oxidation reaction can be run in an organic solvent, e g, a halogenated hydrocarbon such as chloroform.
Those steroids of formula I wherein R, is acyloxyalkyl can be prepared by first 15 oxidizing a steroid of formula V, wherein R', is alkyl, using one equivalent of oxidizing agent, to obtain a steroid having the formula 0 alkyl R d 6 A 17-alkylsulfinyl steroid of formula X can be reacted with an appropriate acid anhydride, and a basic catalyst such as the sodium salt of the corresponding acid, to 20 yield the corresponding 17 ll(acyloxy)alkyllthiolsteroid having the formula 1,603,566 4 1,603,566 4 0 It S-alkyl-O-C-Y R I XI l R 6 Reaction of a steroid of formula XI with a benzocyclobutene of formula VI yields a product of formula I wherein R, is acyloxyalkyl and X is divalent sulfur These steroids can be oxidized as described above to yield the corresponding steroids of formula I wherein X is 5 O O 1 11 -S or -S-.
II 0 The 1 11/3-acyloxy derivatives of formula I can be obtained by acylating the corresponding 11/3-hydroxy steroid of formula I, by acylating the corresponding l 11/3-hydroxy steroid of formula II and proceeding as described above, or by acylating a corresponding 11/3-hydroxy steroid intermediate and proceeding as 10 described above.
Additional processes for preparing the steroids of formula I are available For example, the steroids of formula I wherein X is 0 11 -SH can be prepared by first oxidizing a steroid of formula V with two or more 15 equivalents of oxidizing agent and subsequently reacting the resultant 17sulfonylA 16-steroid with a benzocyclobutene of formula VI.
The oxidation of a 17-thio product to yield a 17-sulfinyl steroid of formula I results in a mixture of two isomers, which may be separated using conventional techniques 20 The steroids of formula I can be used in lieu of known glucocorticoids in the treatment of inflammatory conditions; e g, rheumatoid arthritis They can be administered in the same manner as hydrocortisone, the dosage being adjusted for the relative potency of the particular steroid They may for example be in the form of tablets, capsules, elixirs or sterile aqueous injectable preparations Additionally, 25 the steroids of this invention can be used topically in lieu of known glucocorticoids in the treatment of skin conditions such as dermatitis, psoriasis, sunburn, neurodermatitis, eczema or anogenital pruritus.
When given orally, the steroids of this invention may be used in a dosage range of 0 1 to 200 milligrams, preferably 0 3 to 100 milligrams, for a 70 kg mammal If 30 administered topically, the steroids of this invention may be used in the range of 0.01 to 5 0 % by weight, preferably 0 05 to 2 0 % by weight, in a conventional cream, ointment, lotion or the like.
The following Examples are specific embodiments of this invention.
Example 1 35
9-Fluoro 1 ',2 ',3 ',4 '-tetrahydro 11/3-hydroxy-17-(methylthio)androsta 1,4-dienol 16 a,17 a-blnaphthalene-3-one A) 9 Fluoro 11/3 hydroxy 17,17 bis(methylthio)androsta 1,4 dien 3 one A solution of 9 fluoro 11/3 hydroxyandrosta 1,4 diene 3,17 dione 40 ( 2.0 g) in glacial acetic acid ( 25 ml) is mixed at room temperature with a solution of methanethiol ( 2 4 g) in dichloromethane ( 16 ml) and boron trifluoride etherate ( 0 5 ml) After 1 5 hours, the mixture is poured into water and diluted with chloroform.
1,603,566 The organic layer is then separated, washed with a dilute sodium bicarbonate solution and water, dried and evaporated in vacuo The residue is absorbed on a column of silica gel ( 50 g) Elution of the column with chloroform removed the non-steroidal impurities and a product resulting from thiol addition to A'.
Subsequent elution with chloroform affords the desired material as a solid ( 975 5 mg) Finally, elution with chloroform-ethyl acetate ( 95:5) affords the unreacted steroid ( 345 mg) A specimen of the 957 mg solid is crystallized once from chloroform-methanol to afford the analytical sample of the title compound, melting point 305 C (dec).
Anal Calc'dfor C 2,H 29 FO 252: C,63 60; H,7 37; F,4 79; S,16 17; 10 Found: C,63 48; H,7 21; F,4 95; S, 16 21 B) 9 Fluoro 11/3 hydroxy 17 (methylthio)androsta 1,4,16 trien 3 one A suspension of 9 fluoro 11/3 hydroxy 17,17 bis(methylthio)androsta 1,4 diene 3 one ( 3 6 g) in diethylbenzene ( 250 ml) is 15 slowly distilled from a bath at 220 C.
In a few minutes, a clear solution results and the starting material disappears.
On cooling in an ice bath, the solution deposits small needles of the analytical specimen of the title compound, ( 2 9 g), melting point 268 C (dec) (discoloration starts at 263 C) 20 Anal Calc'd for C 20 H 25 F 02 S: C, 68 93; H, 7 23; F, 5 00; S, 9 20 Found: C, 68 68; H, 7 20; F, 4 92; S, 9 09 C) 9 Fluoro 1 ',2 ',3 ',4 ' tetrahydro 11/3 hydroxy 17 (methylthio)androsta 1,4 dienol 16 a,17 a-blnaphthalene 3 one A suspension of 9 fluoro 11/3 lhydroxy 17 (methylthio)androsta 25 1,4,16 trien 3 one ( 1 0 g) in benzocyclobutene ( 35 ml) is refluxed under an atmosphere of nitrogen In 40 hours, a clear solution results After 90 hours, distillation of the mixture affords unreacted benzocyclobutene ( 10 g) The residual oil is cooled, diluted with chloroform-hexane ( 1:1) and absorbed on a column of silica gel ( 60 g) Elution of the column with chloroform-exhane ( 1:1 to 7:3) removes 30 decomposition products from benzocyclobutene Further elutions with chloroform afford a mixture of the starting material and the title compound ( 1 05 g) and the homogeneous title compound ( 250 mg) The mixture of starting material and product is then rechromatographed over silica gel ( 50 g) to isolate another crop of the homogeneous title compound ( 276 mg) The 250 mg and 276 mg crops are 35 combined and after one crystallization from chloroform-ethyl acetate afford 376 mg of the analytical specimen, melting point 265-267 C (dec, discoloration starts at about 250 C).
Anal Calc'd for C 28 H 33 FO 2 S: C, 74 30; H, 7 34; F, 4 20; S, 7 08 Found: C, 73 98; H, 7 29; F, 4 20; S, 6 76 40 Example 2
9-Fluoro 1 ',2 ',3 ',4 '-tetrahydro 1 1/3-hydroxy 17-(methylsulfonyl)androsta-l,4-dienol 16 a, 17 a-blnaphthalene-3-one A) 9 Fluoro 11/3 hydroxy 17 (methylsulfonyl)androsta 1,4,16 triene 3 one 45 A solution of 9 fluoro 11/3 l hydroxy 17 (methylthio)androsta 1,4,16 triene 3 one ( 1 0 g, see Example l B) is dissolved by warming in a mixture of chloroform ( 130 ml) and absolute ethanol ( 20 ml) The solution is then cooled to room temperature and a solution of m-chloroperbenzoic acid ( 1 1 g of 90 % peracid) is added After 1 0 hour, the solution is washed with a dilute potassium carbonate 50 solution and water, dried and evaporated to a solid This is washed with hot ethyl acetate and filtered to afford the title compound as a colorless solid ( 1 06 g), melting point 335-337 C (dec).
B) 9 Fluoro 1 ',2 ',3 ',4 ' tetrahydro 11/3 hydroxy 17 (methylsulfonyl)androsta 1,4 dienol 16 a,17 a-blnaphthalene 3 one 55 A solution of 9 fluoro 11/3 l hydroxy 17 (methylsulfonyl)androsta 1,4,16 triene 3 one ( 0 5 g) in dichlorobenzene ( 20 0 ml) and benzocyclobutene ( 4.0 ml) is heated in a bath at 170-175 C under nitrogen for 40 hours The solution is then cooled, poured on a column of silica gel ( 35 g) and the column eluted successively with chloroform-hexane ( 1:1), chloroform and chloroformethyl 60 acetate ( 8:2 and 1:1) to afford from the chloroform-ethyl acetate eluates the title 1,603,566 compound ( 585 mg), which had a trace of a less polar impurity as shown by thinlayer chromatography Dissolution of this in ethyl acetate containing some methanol, evaporation of most of the methanol on a steam bath and cooling to ambient temperature affords 270 mg of the homogeneous analytical specimen of the title compound, melting point 254-255 C (dec; discoloration starting from 5 250 C).
Anal Calc'd for C 28 H 33 FO 4 S: C, 69 39; H, 6 86; F, 3 92; S, 6 62 Found: C, 69 30; H, 6 73; F, 4 07; S 6 60 Example 3
4 '/3-Ethoxy-9-fluoro1 ',2 ',3 ',4 '-tetrahydro11 /3-hydroxy17-(methyl 10 sulfonyl)androsta 1,4-dienol 16 a, 17 a-blnaphthalene-3-one A solution of 9 fluoro 113 p hydroxy 17 (methylsulfonyl)androsta 1,4,16 triene 3 one ( 400 mg, see Example 2 A) in a mixture of dry toluene ( 125 ml) and dry o-dichlorobenzene ( 30 ml) containing lethoxybenzocyclobutene ( 0 7 ml) is heated in a bath at 125 C for 3 0 hours The solution is then cooled and 15 absorbed on a dry column of silica gel ( 35 g) The column is eluted successively with chloroform-hexane ( 1:1), chloroform and chloroform-ethyl acetate ( 3:1) to afford from the eluates of the last two solvents the title compound ( 619 mg) contaminated with some impurities Two crystallizations of this material from ethyl acetate-hexane afford needles of the homogeneous title compound ( 430 mg), 20 melting point 258-260 C (dec, discoloration starts from 250 C).
Anal Calc'dfor C 30 H 37 F Os S: C, 68 15; H,7 06; F, 3 59; S, 6 06 Found: C, 67 89; H, 7 07; F, 3 83; S, 5 99 Example 4
17-ll(Acetyloxy)methyllsulfonyll-9-fluorol',2 ',3 ',4 '-tetrahydro 25 I p 1/3-hydroxyandrosta-1,4-dienol 16, 17 a-blnaphthalene-3-one A) 9 Fluoro 1 I/3hydroxy 17 (methylsulfinyl)androsta 1,4,16 trien 3 one To a stirred solution of 1 0 g of 9 fluoro 11/ 3 hydroxy 17 (methylthio)androsta 1,4,16 trien 3 one (see Example IB) in chloroform 30 ( 500 ml) is added a solution of 85 % m-chloroperbenzoic acid ( 552 mg) in chloroform ( 10 ml) in the course of 3 0 minutes In less than 10 minutes, the peracid and the starting steroid disappear The solution is then washed with a dilute potassium carbonate solution and water, dried, concentrated (to about 10 ml) and diluted with ethyl acetate resulting in the precipitation of small, light needles of the 35 analytical specimen of the title compound, ( 1 0 g), melting point 268269 C (dec).
This is a mixture of the two sulfinyl isomers.
Anal Calc'd for C 20 H 25 FO 3 S: C, 65 90; H, 6 90; F, 5 00; S, 8 80 Found: C, 65 76; H, 6 98; F, 4 92; S,9 09 B) 17 ll(Acetyloxy)methyllthiol 9 fluoro 11/3 hydroxyandrosta 1,4,16 40 trien 3 one A mixture of 1 5 g of 9 fluoro I 1/3 hydroxy 17 (methylsulfinyl)androsta 1,4,16 trien 3 one, 70 ml of acetic anhydride and 2 g of fused sodium acetate is heated at 110 C under nitrogen for 2 hours The acetic anhydride is partially removed by distillation under vacuum and the resulting slurry 45 is diluted with 1:1 chloroform-water The organic layer is separated, washed with diluted sodium bicarbonate solution, water, dried over anhydrous sodium sulfate and evaporated in vacuo The residue is dissolved in 4:1 chloroform-hexane and chromatographed on a 40 g-silica gel column Elution with 1:4 hexanechloroform gives 940 mg of slightly impure material Two crystallizations from acetone-hexane 50 give 350 mg of the title compound, melting point 193-194 C.
Anal Calc'd for C 22 H 27 F 04 S: C, 65 00; H, 6 70; F, 4 67; S 7 89 Found: C,64 75; H,6 73; F,4 39; S,8 15 C) 17 ll(Acetyloxy)methyllsulfonyll 9 fluoro 11/3 hydroxyandrosta 1,4,16 triene 3 one 55 To a solution of 17 ll(acetyloxy)methyllthiol 9 fluoro 11 B hydroxyandrosta 1,4,16 triene 3 one ( 507 6 mg) in chloroform ( 25 ml) is added a solution of 85-90 % m-chloroperbenzoic acid ( 508 mg) in chloroform at ambient temperature Within a few minutes the starting material disappears The solution is then washed with a dilute sodium bicarbonate solution and water, dried 60 and evaporated to afford 550 mg of the title compound as a solid This contains only traces of impurities by thin layer chromatography and is used directly for the 1,603,566 next reaction A specimen ( 50 mg) is crystallized from ethyl acetatetoluene to afford 38 mg of the title compound as heavy prisms, melting point 186-187 C.
D) 17 ll(Acetyloxy)methyllsulfonyll 9 fluoro 1 ',2 ',3 ',4 ' tetrahydro 11/3 l hydroxyandrosta 1,4 dienol 16 a,17 a-bl naphthalene 3 one A solution of 17 ll(acetyloxy)methyllsulfonyll 9 fluoro 11/3 5 hydroxyandrosta 1,4,16 triene 3,20 dione ( 350 mg) and benzocyclobutene ( 1.0 ml) in o-dichlorobenzene ( 4 0 ml) containing 4,4 ' thiobis 6 t butyl m cresol ( 10 mg) is heated in a bath at 170 C for 24 hours in an atmosphere of dry nitrogen Another 1 0 ml of benzocyclobutene is then added and the reaction is continued for 5 0 hours The mixture is cooled, poured on a column of silica gel ( 30 10 g) and the column eluted successively with chloroform-hexane ( 1:1), chloroform and chloroform-ethylacetate ( 8:2) to afford successively in these solvents a nonsteroidal oil, a steroidal material ( 80 mg) and a mixture of the starting material and the title compound ( 280 mg) The 280 mg crop is subjected to preparative thin layer chromatography (one 2 0 x 200 x 200 mm silica gel plate, 3 developments) with 15 chloroform-methanol ( 97:3) to isolate the title compound ( 190 mg) One crystallization from ethyl acetate affords the homogeneous analytical specimen as small crystals ( 165 mrg), melting point 246-248 C (dec, discoloration starts from about 210 C) with consistent spectral data.
Anal Calc'd for C 30 H 3 s F Oe S: C, 66 40; H, 6 50; F, 3 50; S, 5 91 20 Found: C,66 21; H,6 38; F,3 45; S,5 79 Example 5
17-ll(Acetyloxy)methyllsulfonyll-4 '/3-ethoxy-9-fluoro 1 ',2 ',3 ',4 '-tetrahydro I p 1/3-hydroxyandrosta 1,4-dieno l 16 a, 17 a-blnaphthalene-3-one 25 A solution of 17 ll(Acetyloxy)methyllsulfonyll 9 fluoro 11/3 hydroxyandrosta 1,4,16 triene 3 one ( 500 mg, see Example 4 C) in toluene ( 15 ml) containing l-ethoxybenzocyclobutene ( 0 5 g) is heated in a bath at 120 C under nitrogen for 2 0 hours when the starting material disappears The solution is then evaporated and the residue subjected to chromatography on a 30 column of silica gel ( 20 g) Elution of the column with chloroform-hexane ( 1:1) affords first non-steroidal impurities (Further elution with this solvent mixture affords a solid ( 350 mg), which on the basis of spectral data and thin layer chromatography behavior is believed to be the 11 lethoxy( 2 methylphenyl)methyllether of the title compound) Further elution of the column 35 with chloroform and chloroform-ethyl acetate ( 9:1) affords the title compound ( 358 mrg) Two crystallizations from ethyl acetate afford the analytical specimen ( 228 mrg), melting point 160-210 C (dec, decomposes with gas evolution at 160 C and melts completely at 210 C).
Anal Calc'd for C 32 H 39 FO 7 S: C, 65 51; H, 6 70; F, 3 00; S, 5 46 40 Found: C, 65 22; H,6 63; F, 3 16; S,5 35 Example 6
9-Fluoro I ',2 ',3 ',4 '-tetrahydro 1 1/3 l-hydroxy 17-(methylsulfinyl)androsta-1,4-dienol 16 a,17 a-bl naphthalene-3-one (isomers A and B) To a stirred solution of 9 fluoro 1 ',2 ',3 ',4 'tetrahydro 11/3 hydroxy 45 17 (methylthio)androsta 1,4 dienol 16 ox,17 ao-blnaphthalene 3 one ( 527 mg, see Example I) in dichloromethane ( 30 ml) at room temperature is added dropwise a solution of 85 % m-chloroperbenzoic acid ( 238 mg) in dichloromethane ( 15 ml) In less than 20 minutes the starting steroid and the peracid disappear as indicated respectively by thin-layer chromatography and a starch-potassium iodide paper 50 test The solution was then washed with a dilute potassium carbonate solution and water, dried, evaporated and was subjected to preparative layer chromatography to isolate compounds as solids These are listed below in the order of increasing Rf values.
Compound Weight 55 1 246 mg 2 209 mg 3 40 mg Compound 1 ( 246 mg) is crystallized once from chloroform-ethyl acetate to afford the analytical specimen of the title compound (Isomer A), melting point 60 297-298 C (dec).
1,603,566 8 1,603,566 8 Anal Calc'd for C 28 H 33 FO 3 S: C, 71 77; H, 7 10: F, 4 05; S, 6 84 Found: C,71 99; H,7 24; F,4 31; S,6 96 Compound 2 ( 209 mg) is crystallized once from chloroform-ethyl acetate to afford the analytical specimen of Isomer B ( 180 mg), melting point 255256 C (dec) 5 Anal Calc'd for C 28 H 33 FO 3 S: C, 71 77; H, 7 10; F, 4 05; S, 6 84 Found: C,71 54; H,6 99; F,4 15; S,6 74 Examples 7-17
Following the procedure of Example 1, but substituting the steroid listed in column I for 9 fluoro 1 l/ hydroxyandrosta 1,4 diene 3,17 dione, the 10 compound listed in column II for methanethiol, and the compound listed in column III for benzocyclobutene, yields the steroid listed in column IV.
C 6 lumn I 7) 1 lp-hydroxyandrosta-1,4diene-3,17-dione 8) 9-bromoandrost-4-ene3,11,17-trione Column II thiophenol ethanethiol Column III trans-I,2-diethoxybenzocyclobutene I 1-ethyl-benzocyclobutene Column IV I 'P,4 '3-diethoxy 1 ',2 ',3 ',4 'tetrahydro II /3-hydroxy 17(phenylthio)androsta 1 l,4-dienol 16 a, 17 a-blnaphthalene-3-one 9-bromo-4 '/3-ethyl 17-(ethylthio)I ',2 ',3 ',4 '-tetrahydroandrost4-enol 16 a, 17 a-blnaphthalene-3,11 dione 9) 9-fluoro 1 1 P-hydroxyandrosta1,4-diene-3,17-dione 10) 1 l/3-hydroxyandrost-4-ene3,17-dione 11) 9-chloro 1/3 P-hydroxyandrosta1,4-diene-3,17-dione 12) 9-iodo-11/3-hydroxyandrosta1,4-diene-3,17-dione 13) 9-fluoro 1 1/-hydroxyandrosta1,4-diene-3,17-dione 14) 9-fluoro 1/3-hydroxyandrost4-ene-3,17-dione n-butanethiol n-propanethiol thiophenol 1-mercapto-2methylbenzene 1 -mercapto-2methoxybenzene 1-chloro-4mercaptobenzene I-carbomethoxybenzocyclobutene I -formylbenzocyclobutene 1-acetyloxybenzocyclobutene 1-acetylbenzocyclobutene trans-I,2-dibromobenzocyclobutene trans 1,2-dihydroxybenzocyclobutene 17-(butylthio)-9-fluoro 1 ',2 ',3 ',4 'tetrahydro 11 /3-hydroxy-3-oxoandrosta1,4-dienol 16 a, 17 a-blnaphthalene 4 '/3-carboxylic acid, methyl ester 4 'p 3-formyl 1 ',2 ',3 ',4 '-tetrahydro1 l/3-hydroxy 17-(propylthio)androst4-enol 16 a, 17 a-blnaphthalene-3-one 4 '/3-(acetyloxy)-9-chloro 1 ',2 ',3 ',4 'tetrahydro 1 l/3-hydroxy 17-(phenylthio)androsta 1,4-dienol 16 a, 17 a-blnaphthalene-3-one 4 '/3-acetyl 1 ',2 ',3 ',4 '-tetrahydro1 l/3-hydroxy-9-iodo-17-l( 2-methylphenyl)thiol androsta I,4-dienol 16 a, 17 a-blnaphthalene-3-one 1 '/3,4 '/3-dibromo-9-fluoro1 ',2 ',3 ',4 '-tetrahydro-1 1/3hydroxy 17-l( 2-methoxyphenyl)thiol androsta I,4-dienol 16 a, 17 a-bl naphthalene-3-one 17-l( 4-chlorophenyl)thiol 9fluoro ',2 ',3 ',4 '-tetrahydro '1,4 'P, 1 13-trihydroxyandrost-4-enol 16 a, 17 a-blnaphthalene-3-one C 0 O' x 15) 1 1 13-hydroxyandrosta-1,4diene-3, 17-dione 16) 1 1/3-hydroxyandrosta-1,4-diene3,17-dione 17) 6 a,9-difluoro-1 1 p/3-hydroxyandrost-4-ene-3,17-dione methanethiol methanethiol 1-bromo-4mercaptobenzene 1-phenylbenzocyclobutene 1-cyanobenzocyclobutene trans-I,2-dihydroxybenzocyclobutene 0 \ C., I ',2 ',3 ',4 '-tetrahydro 1 lphydroxy 1 7-(methylthio)-4 '/3phenylandrosta 1,4-dienol 16 a, 17 a-bl naphthalene-3-one I ',2 ',3 ',4 '-tetrahydro 1 13hydroxy 1 7-(methylthio)3-oxoandrosta 1,4-dienol 16 a, 17 a-blnaphthalene-4 '/3carbonitrile 17-l( 4-bromophenyl)thiol-6 a,9-difluoroI ',2 ',3 ',4 '-tetrahydroI '/3,4 '3, 1 lp/3-trihydroxyandrost4-enol 16 a, 17 a-blnaphthalene-3one { 11 1,603,566 11
Claims (1)
WHAT WE CLAIM IS:-
1 A steroid having the formula Rl 6 or the 1,2-dehydro derivative thereof, wherein X is -S-, O O 11 II -S or -S-; 5 11 0 R 1 is alkyl, aryl or acyloxyalkyl; R 2 and R 3 are the same or different and are hydrogen, alkyl, alkoxy, carboalkoxy, formyl, O O II II alkyl-C, alkyl-C-O-, hydroxy, halogen, phenyl or cyano, with the proviso that when R 2 and R 3 are different, one of R 2 and R 3 is hydrogen; R 4 is carbonyl, 3hydroxymethylene or /3 10 acyloxymethylene; Rs is hydrogen or halogen; and R 6 is hydrogen or fluorine; wherein the term "aryl" refers to phenyl or phenyl substituted with one or two alkyl, alkoxy or halogen substituents; the term "acyloxy" refers to a group having the formula 0 Y-C-O 15 is 15 wherein Y is alkyl or aryl; and the terms "alkyl" and "alkoxy" refer to groups having I to 10 carbon atoms.
2 A steroid in accordance with claim 1 wherein X is -S-.
3 A steroid in accordance with claim 1 wherein X is 0 II -S- 20 4 A steroid in accordance with claim I wherein X is 0 II -S-.
II A steroid in accordance with any one of claims 1-4 wherein R 1 is alkyl.
6 A steroid in accordance with any one of claims 1-4 wherein R 1 is aryl.
7 A steroid in accordance with any one of claims 1-4 wherein R 1 is 25 acyloxyalkyl.
8 A steroid in accordance with any one of claims 1-7 wherein R 2 and R 3 are hydrogen.
9 A steroid in accordance with any one of claims 1-8 wherein R 4 is /hydroxymethylene, R 5 is fluorine, and R 6 is hydrogen 30 ll 1,603,566 12 1,603,566 12 The steroid in accordance with claim 1, 9 fluoro 1 ',2 ',3 'Y,4 ' tetrahydro 113 hydroxy 17 (methylthio)androsta 1,4 dienol 16 ca,17 ablnaphthalene-3-one.
11 The steroid in accordance with claim 1, 9 fluoro 1 ',2 ',3 ',4 ' tetrahydro 11/3 hydroxy 17 (methylsulfonyl)androsta 1,4 dienoll 6, 17 oa 5 blnaphthalene 3 one.
12 The steroid in accordance with claim 1, 4 '3-ethoxy 9 fluoro,2 ',Y,4 ' tetrahydro 11/3 hydroxy 17 (methylsulfonyl)androsta 1,4dienol 16 a,17 a-blnaphthalene 3 one.
13 The steroid in accordance with claim 1, 17 10 ll(acetyloxy)methyllsulfonyll 9 fluoro 1 ',2 ',3 ',4 ' tetrahydro 113 hydroxyandrosta 1,4 dienol 16 a,17 a-blnaphthalene 3 one.
14 The steroid in accordance with claim 1, 17 ll(acetyloxy)methyllsulfonyll 4 '/3 ethoxy 9 fluoro 1 ',2 ',3 ',4 ' tetrahydro 11/3 hydroxyandrosta 1,4 dienol 16 a,17 a-blnaphthalene3 one 15 The steroid in accordance with claim 1, 9 fluoro l',2 ',3 ',4 ' tetrahydro 11/3 hydroxy 17 (methylsulfinyl)androsta 1,4 dienol 16 ca,17 ablnaphthalene 3 one.
16 A process for the preparation of a steroid having the formula 20 H 6 or the 1,2-dehydro derivative thereof, wherein X is -S-, O O II tl 11 11 -S or -S-; II 11 0 R, is alkyl, aryl or acyloxyalkyl; R 2 and R 3 are the same or different and are hydrogen, alkyl, alkoxy, carboalkoxy, formyl, O O II II alkyl-C-, alkyl-C-O, 25 hydroxy, halogen, phenyl or cyano, with the proviso that when R 2 and R 3 are different, one of R 2 and R 3 is hydrogen; R 4 is carbonyl, /3hydroxymethylene or /3acyloxymethylene; R 5 is hydrogen or halogen; and R 6 is hydrogen or fluorine; wherein the term "aryl" refers to phenyl or phenyl substituted with one or two alkyl, alkoxy or halogen substituents; the term "acyloxy" refers to a group having 30 the formula 0 11 II Y-C-Owherein Y is alkyl or aryl; and the terms "alkyl" and "alkoxy" refer to groups having 1 to 10 carbon atoms, which comprises reacting a steroid of the formula R 35 A 6 with a benzocyclobutene of the formula óo R 2 3 to form a steroid product wherein X is divalent sulfur, and optionally oxidizing this product to form the corresponding sulfinyl product or the corresponding sulfonyl product 5 17 A steroid in accordance with Claim 1 when prepared by the process of Claim 16.
18 A steroid in accordance with Claim 1 as named in any of Examples 7-17.
19 A pharmaceutical composition comprising a steroid in accordance with any one of Claims I to 15, 17 or 18 and a pharmaceutical carrier 10 A composition according to Claim 19 in the form of a tablet, capsule, elixir or sterile aqueous injectable preparation.
21 A composition according to Claim 19 in the form of a cream ointment or lotion.
For the Applicants, D YOUNG & CO, Chartered Patent Agents, 9 & 10, Staple Inn, London WCIV 7RD.
Printed for Her Majesty's Stationery Office, by the Courier Press, Leamington Spa, 1981 Published by The Patent Office, 25 Southampton Buildings, London, WC 2 A l AY, from which copies may be obtained.
1,603,566
GB16545/78A
1977-05-12
1978-04-26
Steroidal naphthalenes
Expired
GB1603566A
(en)
Applications Claiming Priority (1)
Application Number
Priority Date
Filing Date
Title
US05/796,292
US4091036A
(en)
1977-05-12
1977-05-12
17-Alkylthio (and arylthio)-1',2',3',4'-tetrahydroandrosteno [16 α, 17 α-b]naphthalenes and derivatives
Publications (1)
Publication Number
Publication Date
GB1603566A
true
GB1603566A
(en)
1981-11-25
Family
ID=25167835
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
GB16545/78A
Expired
GB1603566A
(en)
1977-05-12
1978-04-26
Steroidal naphthalenes
Country Status (6)
Country
Link
US
(1)
US4091036A
(en)
JP
(1)
JPS53141249A
(en)
CA
(1)
CA1114807A
(en)
DE
(1)
DE2820636A1
(en)
FR
(1)
FR2390454A1
(en)
GB
(1)
GB1603566A
(en)
Families Citing this family (14)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US4183924A
(en)
*
1978-02-27
1980-01-15
Schering Corporation
17α-Chloro-17β-hydrocarbonsulfinyl-1,4-androstadienes and the corresponding 17β-hydrocarbonsulfonyl derivatives and their use as anti-acne agents
US4252733A
(en)
*
1980-03-31
1981-02-24
E. R. Squibb & Sons, Inc.
17-Substituted sulfonyl-16,16-disubstituted androstenes
US4265815A
(en)
*
1980-03-31
1981-05-05
E. R. Squibb & Sons, Inc.
17-(Substituted thio)androst-4-ene[16,17,-b]-[1,4]benzodioxin-3-ones
US4361559A
(en)
*
1981-08-20
1982-11-30
E. R. Squibb & Sons, Inc.
Antiinflammatory 17,17-bis (substituted thio) androstenes
US4397782A
(en)
*
1982-05-28
1983-08-09
E. R. Squibb & Sons, Inc.
Antiinflammatory 17-spiroandrostenes
US4447363A
(en)
*
1982-07-07
1984-05-08
E. R. Squibb & Sons, Inc.
Androstene-17-dithioketals
US4446071A
(en)
*
1982-09-09
1984-05-01
E. R. Squibb & Sons, Inc.
Intermediates useful in the preparation of 17,17-bis(substituted thio) androstenes
US4435326A
(en)
*
1982-09-09
1984-03-06
E. R. Squibb & Sons, Inc.
Intermediates useful in the preparation of 17,17-bis(substituted thio)androstenes
US4420428A
(en)
*
1982-12-27
1983-12-13
E. R. Squibb & Sons, Inc.
16-Ketoandrostene-17-dithioketals
US4427592A
(en)
*
1983-01-31
1984-01-24
E. R. Squibb & Sons, Inc.
Androstene-17-dithioketals
US4481144A
(en)
*
1984-02-03
1984-11-06
E. R. Squibb & Sons, Inc.
17-Substituted thia-17-alkyl(or alkenyl or alkynyl)androstenes
US4529548A
(en)
*
1984-05-07
1985-07-16
E. R. Squibb & Sons, Inc.
17β-(substituted thio)androstenes
US4529547A
(en)
*
1984-06-20
1985-07-16
E.R. Squibb & Sons, Inc.
17-(substituted thio)-17-(substituted dithio)androstenes
US4528138A
(en)
*
1984-06-20
1985-07-09
E. R. Squibb & Sons, Inc.
16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
Family Cites Families (4)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US3971773A
(en)
*
1974-11-08
1976-07-27
E. R. Squibb & Sons, Inc.
Steroidal 9,11-dihalo-[16α,17-b]1,4-dioxanes
US3937720A
(en)
*
1974-11-25
1976-02-10
E. R. Squibb & Sons, Inc.
Steroidal[16α,17-β]naphthalenes
US3944584A
(en)
*
1975-02-03
1976-03-16
E. R. Squibb & Sons, Inc.
Steroidal (16α,17-d)cyclohexenes
US3994935A
(en)
*
1975-11-24
1976-11-30
E. R. Squibb & Sons, Inc.
Steroidal 16β-alkyl[16α,17-b]naphthalenes
1977
1977-05-12
US
US05/796,292
patent/US4091036A/en
not_active
Expired - Lifetime
1978
1978-04-20
CA
CA301,586A
patent/CA1114807A/en
not_active
Expired
1978-04-26
GB
GB16545/78A
patent/GB1603566A/en
not_active
Expired
1978-05-11
DE
DE19782820636
patent/DE2820636A1/en
not_active
Withdrawn
1978-05-12
FR
FR7814308A
patent/FR2390454A1/en
active
Granted
1978-05-12
JP
JP5705778A
patent/JPS53141249A/en
active
Pending
Also Published As
Publication number
Publication date
DE2820636A1
(en)
1978-11-16
US4091036A
(en)
1978-05-23
FR2390454A1
(en)
1978-12-08
JPS53141249A
(en)
1978-12-08
CA1114807A
(en)
1981-12-22
FR2390454B1
(en)
1981-11-27
Similar Documents
Publication
Publication Date
Title
GB1603566A
(en)
1981-11-25
Steroidal naphthalenes
EP0073026B1
(en)
1986-03-19
17,17-bis(substituted thio)-3-ketoandrostenes and pharmaceutical compositions
PT1831239E
(en)
2010-05-06
A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid lambda-lactone and key-intermediates for this process
US4146538A
(en)
1979-03-27
17-Alkylthio (and arylthio) androsteno[17α,16α-b]benzopyran-3-ones and [16α,17α]naphthopyran-3-ones
US4094840A
(en)
1978-06-13
17-Alkylthio (and arylthio) androsteno[16α,17α-b]benzodioxin-3-ones
GB2025421A
(en)
1980-01-23
13-alkylthio (and arylthio-11,17-epoxy-17-methyl-18-norandrostenes
US2684963A
(en)
1954-07-27
Process for producing 17-bromo steroids
US4420428A
(en)
1983-12-13
16-Ketoandrostene-17-dithioketals
US4265815A
(en)
1981-05-05
17-(Substituted thio)androst-4-ene[16,17,-b]-[1,4]benzodioxin-3-ones
US3480622A
(en)
1969-11-25
Process for the preparation of debrominated analogues of bromo-steroids of the pregnane,androstane and cholestane series
US4427592A
(en)
1984-01-24
Androstene-17-dithioketals
GB1582551A
(en)
1981-01-14
Steroidal (16a, 17-c) (2h) pyrroles
US4220588A
(en)
1980-09-02
Chemical processes
US2908694A
(en)
1959-10-13
7-substituted thio-4-androstenes
US3767683A
(en)
1973-10-23
2-((estra-1,3,5-(10)-trien-2-yl)thio)-2-methyl-propionic acid derivatives
US3169128A
(en)
1965-02-09
Steroidal 2beta, 3alpha-diol cyclic trithiocarbonate
US2847427A
(en)
1958-08-12
Delta or 5,16 androstadien-17-alkylsulfones and sulfoxides
US3033859A
(en)
1962-05-08
Process for the manufacture of oxido-steroids
Draper
1983
Synthesis of steroidal azides. Part 1. Stereospecific vicinal azidohydroxylation of steroidal olefins
GB1603911A
(en)
1981-12-02
Steroidal (16,17-b)benzodioxins
AOYAMA et al.
1971
Boron Trifluoride-catalyzed D-Homo Rearrangements of 20β-Acetoxy-5α-pregnanes
US2806042A
(en)
1957-09-10
17-alkylsulfonyl and 17-alkylsulfinyl substitution products of 5-androsten-3-ol and esters thereof
Morrow et al.
1964
Some 20-substituted 21-norprogesterone derivatives
Tomoeda et al.
1967
The Polyphosphoric Acid-Catalyzed Ring Opening of 4, 5-Epoxy-3-oxo Steroids. IV. The Synthesis of 17α-Hydroxy-4-ethylthiopregn-4-ene-3, 20-dione and Its Analogs
Dabović et al.
1994
Photochemically induced mercuric oxide-iodine oxidation of some unsaturated steroid compounds
Legal Events
Date
Code
Title
Description
1982-05-12
PS
Patent sealed [section 19, patents act 1949]
1985-01-03
PCNP
Patent ceased through non-payment of renewal fee
Download PDF in English
